• No results found

First record of a Galapagos fur seal (Arctocephalus galapagoensis) in Guatemala

N/A
N/A
Protected

Academic year: 2020

Share "First record of a Galapagos fur seal (Arctocephalus galapagoensis) in Guatemala"

Copied!
8
0
0

Loading.... (view fulltext now)

Full text

Loading

Figure

Table 1 Marine mammal species naturally occurring inGuatemala (Sirenia: Quintana-Rizzo and Reynolds 2010; cetacea:Quintana-Rizzo and Gerrodette 2009)
Fig. 1 Location of the stranding site, rehabilitation center and release site of the fur seal in Guatemala and the natural distribution ofArctocephalus galapagoensis in the Galapagos Islands
Fig. 2 Photographs ofsagittal crest (the face and forehead over the eyes forming a small pale mask (distinguish this species from otherAsociación de Rescate de Vida Silvestre on 14 June 2016 ( Arctocephalus galapagoensis at Barra El Jiote community on Juti
Fig. 3 Satellites images of anomalous sea surface temperature registered in the eastern tropical Pacific, including the GalapagosIslands, in March (a), April (b), May (c) and June (d) 2016

References

Related documents

Research studies in English or French were eligible for inclusion if they fulfilled the following criteria: quantitative, qualitative and mixed method studies that used

Eight out of ten patient participants and all healthcare professionals observed that all three encounter decision aids aimed to prepare and inform patients of available

MAP: Milk Allergy in Primary Care; CMA: cow’s milk allergy; UK: United Kingdom; US: United States; EAACI: European Academy of Allergy, Asthma and Clinical Immunology; NICE:

It was decided that with the presence of such significant red flag signs that she should undergo advanced imaging, in this case an MRI, that revealed an underlying malignancy, which

Also, both diabetic groups there were a positive immunoreactivity of the photoreceptor inner segment, and this was also seen among control ani- mals treated with a

intervention and control groups was too high, likely based on the fact that our control group also received intensive smoking cessation therapy and that we used the stricter

These results showed that agomelatine 25–50 mg/day was equivalent to fluoxetine 30–40 mg/day in treating depressive symptoms in T2DM subjects, although the subjects receiving

19% serve a county. Fourteen per cent of the centers provide service for adjoining states in addition to the states in which they are located; usually these adjoining states have